Abstract:Motile kinesins are motor proteins that move unidirectionally along microtubules as they hydrolyze ATP. They share a conserved motor domain (head) which harbors both the ATP-and microtubule-binding activities. The kinesin that has been studied most moves toward the microtubule (1)-end by alternately advancing its two heads along a single protofilament. This kinesin is the subject of this review. Its movement is associated to alternate conformations of a peptide, the neck linker, at the C-terminal end of the mo… Show more
“…The amino terminal globular heads of KIF5 form the motor domains and contain ATP and microtubule-binding sites. Kinesin-1 is able to take steps along the microtubule by alternately detaching and advancing each of its two globular heads [104]. High-resolution X-ray crystallography and cryo-electron microscopy of kinesin-1 in complex with tubulin in both ATP-bound and nucleotide-free states have provided insights into how the motor moves [104].…”
Section: Key Figurementioning
confidence: 99%
“…Kinesin-1 is able to take steps along the microtubule by alternately detaching and advancing each of its two globular heads [104]. High-resolution X-ray crystallography and cryo-electron microscopy of kinesin-1 in complex with tubulin in both ATP-bound and nucleotide-free states have provided insights into how the motor moves [104]. ATP binding to the 'front' motor domain not only allows high-affinity binding to microtubules but also triggers conformational changes in the 'rear' globular head that allows it to detach from microtubules and take a step.…”
The intracellular transport of organelles, proteins, lipids, and RNA along the axon is essential for neuronal function and survival. This process, called axonal transport, is mediated by two classes of ATP-dependent motors, kinesins, and cytoplasmic dynein, which carry their cargoes along microtubule tracks. Protein kinases regulate axonal transport through direct phosphorylation of motors, adapter proteins, and cargoes, and indirectly through modification of the microtubule network. The misregulation of axonal transport by protein kinases has been implicated in the pathogenesis of several nervous system disorders. Here, we review the role of protein kinases acting directly on axonal transport and discuss how their deregulation affects neuronal function, paving the way for the exploitation of these enzymes as novel drug targets.
“…The amino terminal globular heads of KIF5 form the motor domains and contain ATP and microtubule-binding sites. Kinesin-1 is able to take steps along the microtubule by alternately detaching and advancing each of its two globular heads [104]. High-resolution X-ray crystallography and cryo-electron microscopy of kinesin-1 in complex with tubulin in both ATP-bound and nucleotide-free states have provided insights into how the motor moves [104].…”
Section: Key Figurementioning
confidence: 99%
“…Kinesin-1 is able to take steps along the microtubule by alternately detaching and advancing each of its two globular heads [104]. High-resolution X-ray crystallography and cryo-electron microscopy of kinesin-1 in complex with tubulin in both ATP-bound and nucleotide-free states have provided insights into how the motor moves [104]. ATP binding to the 'front' motor domain not only allows high-affinity binding to microtubules but also triggers conformational changes in the 'rear' globular head that allows it to detach from microtubules and take a step.…”
The intracellular transport of organelles, proteins, lipids, and RNA along the axon is essential for neuronal function and survival. This process, called axonal transport, is mediated by two classes of ATP-dependent motors, kinesins, and cytoplasmic dynein, which carry their cargoes along microtubule tracks. Protein kinases regulate axonal transport through direct phosphorylation of motors, adapter proteins, and cargoes, and indirectly through modification of the microtubule network. The misregulation of axonal transport by protein kinases has been implicated in the pathogenesis of several nervous system disorders. Here, we review the role of protein kinases acting directly on axonal transport and discuss how their deregulation affects neuronal function, paving the way for the exploitation of these enzymes as novel drug targets.
“…These experiments are technically challenging and depend on ATP analogs and neck linker insertions to specifically affect the duration of the one-head bound state but not the two-head-bound state. Moreover, it is difficult to reconcile this new model with high resolution X-ray crystallography and cryo-electron microscopy studies (27,102). These structures indicate that ATP binding induces a large structural change within the catalytic motor domain that drives docking of the neck linker and therefore immediately results in a forward step.…”
Kinesin-2s are major transporters of cellular cargoes. This subfamily contains both homodimeric kinesins whose catalytic domains result from the same gene product and heterodimeric kinesins with motor domains derived from two different gene products. In this review, we focus on the progress to define the biochemical and biophysical properties of the kinesin-2 family members. Our understanding of their mechanochemical capabilities has been advanced by the ability to identify the kinesin-2 genes in multiple species, expression and purification of these motors for single molecule and ensemble assays, and development of new technologies enabling quantitative measurements of kinesin activity with greater sensitivity.Kinesins constitute a superfamily of microtubule-based molecular motor enzymes that couple the chemical energy from ATP turnover to force production for diverse cellular functions (reviewed in (1-12)). Kinesins are classified into 15 different subfamilies, yet they share a structurally conserved kinesin motor domain (1,3,(13)(14)(15)(16). However, key amino acid residue changes can confer unique mechanochemical properties to each kinesin, which in turn specify cellular function. The N-terminal kinesins are composed of an N-terminal motor domain connected to a long a-helical region that dimerizes into a coiled-coil stalk that ends with a C-terminal domain that may interact with specific adaptor proteins for cargo linkage (Fig. 1). N-kinesin subfamilies include conventional kinesin-1, kinesin-2, kinesin-3, kinesin-5 Eg5/KSP, and kinesin-7 CENP-E, and all are best known for their roles in intracellular transport.N-kinesins carry cargo directionally toward the plus-end of microtubules, which are polymerized from ab-tubulin subunits to form a cylindrical polymer of 13 protofilaments. The kinesins are able to "read" the polarity of the microtubule because of the structural asymmetry of ab-tubulin subunits. The movement of N-kinesins is designated as "processive," which implies that upon microtubule collision, a single, dimeric kinesin steps continuously toward the microtubule plus end in an asymmetric hand-over-hand manner hydrolyzing one ATP per 8-nm step for hundreds of steps (17)(18)(19)(20)(21)(22). The 8-nm step size results from the distance between adjacent ab-tubulin dimers along the microtubule lattice. As Fig. 2 illustrates, a processive kinesin binds the microtubule and then goes through a series of structural transitions, each modulated by nucleotide state. To maintain a processive run with continuous stepping, the
Kinesin-2 Molecular Motors
2ATPase cycle of each head remains out-of-phase with the other to avoid premature release if both heads exist in a microtubule weak binding state simultaneously. The degree of processivity, quantified by "run length," varies between kinesin subfamilies and is regulated by a series of "gating" mechanisms in which a chemical and/or mechanical requirement must be satisfied to proceed forward. There has been significant effort to define the determinants of ...
“…Kinesins including KIFC1 bind to microtubules with their motor domains, and ATP hydrolysis sites [103] included by these motor domains are popular disturbing sites for designed drugs. As KIFC1 has emerged popular as a chemotherapy target, three small-molecule inhibitors of KIFC1 have been thus far highlighted.…”
The kinesin motor KIFC1 has been suggested as a potential chemotherapy target due to its critical role in clustering of the multiple centrosomes found in cancer cells. In this regard, KIFC1 seems to be non-essential in normal somatic cells which usually possess only two centrosomes. Moreover, KIFC1 is also found to initiatively drive tumor malignancy and metastasis by stabilizing a certain degree of genetic instability, delaying cell cycle and protecting cancer cell surviving signals. However, that KIFC1 also plays roles in other specific cell types complicates the question of whether it is a promising chemotherapy target for cancer treatment. For example, KIFC1 is found functionally significant in vesicular and organelle trafficking, spermiogenesis, oocyte development, embryo gestation and double-strand DNA transportation. In this review we summarize a recent collection of information so as to provide a generalized picture of ideas and mechanisms against and in favor of KIFC1 as a chemotherapy target. And we also drew the conclusion that KIFC1 is a promising chemotherapy target for some types of cancers, because the side-effects of inhibiting KIFC1 mentioned in this review are theoretically easy to avoid, while KIFC1 is functionally indispensable during mitosis and malignancy of multi-centrosome cancer cells. Further investigations of how KIFC1 is regulated throughout the mitosis in cancer cells are needed for the understanding of the pathways where KIFC1 is involved and for further exploitation of indirect KIFC1 inhibitors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.